Murilo Freitas - 13:25, 20 de fevereiro de 20181,766
0
Audiences
Healthcare professionals including oncologists, uro-oncologists, urologists, oncology nurses, oncology pharmacists, emergency room staff, and other healthcare professionals providing care to cancer patients, including those working in hospitals, cancer centers, oncology clinics, and pharmacies.
Key messages
Severe cases of myocarditis have been reported in patients being treated with TECENTRIQ (atezolizumab) in clinical trials.
Healthcare professionals are advised to:
monitor patients receiving TECENTRIQ for signs and symptoms of myocarditis.
withhold TECENTRIQ therapy in patients with Grade 2 myocarditis.
permanently discontinue TECENTRIQ treatment in patients with Grade 3 or 4 myocarditis.
administer corticosteroids and/or additional immunosuppressive agents as clinically indicated to TECENTRIQ treated patients who develop myocarditis.
The Canadian Product Monograph has been updated to include this new safety information.
